Design Therapeutics (DSGN) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Design Therapeutics was $79.36 million, up 5.9% year-over-year; for FY2025, it was $79.47 million, up 27.4% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of 56.2% (FY2020 to FY2025).
• In prior years, Design Therapeutics' Operating Expenses was $62.38 million in FY2024 (-20.2%), $78.19 million in FY2023 (+15.7%), $67.59 million in FY2022 (+88.6%) and $35.83 million in FY2021 (+318.8%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses since Q2 2023.
• On a year-over-year basis, Operating Expenses increased in six of the last eight quarters, with growth averaging 13.6%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2021, with growth of 371.8%; the weakest was Q1 2024, with a decline of 33.5%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $19.71 million (Q1 2026), $18.17 million (Q4 2025) and $19.31 million (Q3 2025).